Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
27.5M
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
9.46M
-
Shares change
-
+169K
-
Total reported value, excl. options
-
$56.2M
-
Value change
-
+$983K
-
Number of buys
-
11
-
Number of sells
-
-13
-
Price
-
$5.94
Significant Holders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) as of Q1 2020
33 filings reported holding FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value as of Q1 2020.
FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.46M shares
of 27.5M outstanding shares and own 34.47% of the company stock.
Largest 10 shareholders include Southpoint Capital Advisors LP (4M shares), Avoro Capital Advisors LLC (1.11M shares), Solas Capital Management, LLC (960K shares), 683 Capital Management, LLC (950K shares), Sonic Fund II, L.P. (835K shares), EVENTIDE ASSET MANAGEMENT, LLC (720K shares), GRANAHAN INVESTMENT MANAGEMENT INC/MA (270K shares), Cadence Capital Management LLC (147K shares), OXFORD ASSET MANAGEMENT LLP (130K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (88.5K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.